Cargando…
Free Insulin-like Growth Factor (IGF)-I in Children with PWS
In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911349/ https://www.ncbi.nlm.nih.gov/pubmed/35268371 http://dx.doi.org/10.3390/jcm11051280 |
_version_ | 1784666778244218880 |
---|---|
author | Damen, Layla Elizabeth, Melitza S. M. Donze, Stephany H. van den Berg, Sjoerd A. A. de Graaff, Laura C. G. Hokken-Koelega, Anita C. S. |
author_facet | Damen, Layla Elizabeth, Melitza S. M. Donze, Stephany H. van den Berg, Sjoerd A. A. de Graaff, Laura C. G. Hokken-Koelega, Anita C. S. |
author_sort | Damen, Layla |
collection | PubMed |
description | In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens body composition and quality of life. As clinical features do not seem to correspond to immunoreactive IGF-I values, it is questionable whether immunoreactive IGF-I is a suitable marker for GH dosing, or whether another parameter better reflects IGF-I bioavailability and bioactivity. We, therefore, investigate serum immunoreactive IGF-I, free IGF-I and IGFBP-3 levels in 70 GH-treated children with PWS. Our study showed that, although immunoreactive IGF-I levels were high (>2 SDS) in the vast majority of prepubertal and pubertal children, free IGF-I SDS levels were <0 SDS in most and <1 SDS in all. Free IGF-I correlated with the immunoreactive IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio. We conclude that there is a major discrepancy between immunoreactive and free IGF-I levels. While in the majority of GH-treated children with PWS, immunoreactive IGF-I levels were high, free IGF-I levels were <0 SDS in most. Our data appear to be very reassuring and suggest that free IGF-I levels should also be taken into consideration when the immunoreactive IGF-I levels are >2 SDS in GH-treated children with PWS. |
format | Online Article Text |
id | pubmed-8911349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89113492022-03-11 Free Insulin-like Growth Factor (IGF)-I in Children with PWS Damen, Layla Elizabeth, Melitza S. M. Donze, Stephany H. van den Berg, Sjoerd A. A. de Graaff, Laura C. G. Hokken-Koelega, Anita C. S. J Clin Med Article In children with Prader–Willi syndrome (PWS), the standard growth hormone (GH) dose often results in high immunoreactive IGF-I levels. These high immunoreactive IGF-I levels lead to concern because their long-term effects are unknown. As a result, clinicians have to lower the GH dose, which worsens body composition and quality of life. As clinical features do not seem to correspond to immunoreactive IGF-I values, it is questionable whether immunoreactive IGF-I is a suitable marker for GH dosing, or whether another parameter better reflects IGF-I bioavailability and bioactivity. We, therefore, investigate serum immunoreactive IGF-I, free IGF-I and IGFBP-3 levels in 70 GH-treated children with PWS. Our study showed that, although immunoreactive IGF-I levels were high (>2 SDS) in the vast majority of prepubertal and pubertal children, free IGF-I SDS levels were <0 SDS in most and <1 SDS in all. Free IGF-I correlated with the immunoreactive IGF-I, IGFBP-3 and IGF-I/IGFBP-3 ratio. We conclude that there is a major discrepancy between immunoreactive and free IGF-I levels. While in the majority of GH-treated children with PWS, immunoreactive IGF-I levels were high, free IGF-I levels were <0 SDS in most. Our data appear to be very reassuring and suggest that free IGF-I levels should also be taken into consideration when the immunoreactive IGF-I levels are >2 SDS in GH-treated children with PWS. MDPI 2022-02-26 /pmc/articles/PMC8911349/ /pubmed/35268371 http://dx.doi.org/10.3390/jcm11051280 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Damen, Layla Elizabeth, Melitza S. M. Donze, Stephany H. van den Berg, Sjoerd A. A. de Graaff, Laura C. G. Hokken-Koelega, Anita C. S. Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title | Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title_full | Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title_fullStr | Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title_full_unstemmed | Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title_short | Free Insulin-like Growth Factor (IGF)-I in Children with PWS |
title_sort | free insulin-like growth factor (igf)-i in children with pws |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911349/ https://www.ncbi.nlm.nih.gov/pubmed/35268371 http://dx.doi.org/10.3390/jcm11051280 |
work_keys_str_mv | AT damenlayla freeinsulinlikegrowthfactorigfiinchildrenwithpws AT elizabethmelitzasm freeinsulinlikegrowthfactorigfiinchildrenwithpws AT donzestephanyh freeinsulinlikegrowthfactorigfiinchildrenwithpws AT vandenbergsjoerdaa freeinsulinlikegrowthfactorigfiinchildrenwithpws AT degraafflauracg freeinsulinlikegrowthfactorigfiinchildrenwithpws AT hokkenkoelegaanitacs freeinsulinlikegrowthfactorigfiinchildrenwithpws |